Table 2.
Baseline characteristics of the trials included in the meta-analysis
| First author, year | Mean age (years) | Monotherapy (n) | Combination therapy (n) | UDCA dose (mg/day) | Bezafibrate dose (mg/day) | Duration of treatment (months) | Publication type |
|---|---|---|---|---|---|---|---|
| Nakai et al,20 2000 | 58 | 13 | 10 | 600 | 400 | 12 | Letter |
| Kanda et al,19 2003 | 56 | 11 | 11 | 600 | 400 | 6 | Full text |
| Itakura et al,18 2004 | 57 | 7 | 9 | 600 | 400 | 6 | Full text |
| Iwasaki et al,13 2008 | 54 | 10 | 12 | 600 | 400 | 12 | Full text |
| Hazzan and Tur-Kaspa,16 2010 | 64 | 8 | 8 | 900–1,500 | 400 | 24 | Full text |
| Takeuchi et al,17 2011 | 57 | 22 | 15 | 600 | 400 | 24 | Full text |
| Honda et al,11 2013 | 58 | 31 | 19 | 600 | 400 | 3 | Full text |
| Lens et al,14 2014 | 53 | 28 | 28 | 900–1,500 | 400 | 3 | Full text |
| Hosonuma et al,15 2015 | 64 | 14 | 13 | 600–900 | 400 | 96 | Full text |
Abbreviation: UDCA, ursodeoxycholic acid.